Compare KB Financial Group, Inc. (KB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Neurocrine Biosciences Inc — how do they compare? KB Financial Group, Inc. trades at $122.57 (market cap $42.62B), while Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B). The key difference: KB Financial Group, Inc. is far larger — about 3× Neurocrine Biosciences Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Neurocrine Biosciences Inc for 23 Days on average.
| KB | NBIX | |
|---|---|---|
Market Cap | $42.62B | $14.36B |
Volume | 164,291 | 1,237,180 |
Sector | Financials | Health |
52-Week High | $132.88 | $185.50 |
52-Week Low | $77.50 | $123.10 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $215.53T | $14.37B |
Dividend Yield | 2.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $122.00, down 2.19% on the day, with neutral technical signals despite bullish moving averages. The company demonstrates strong fundamental performance with consistent earnings beats, revenue growth from $21.23T in 2025 to $22.37T projected for 2026, and healthy profit margins above 28%. Recent analyst upgrades to Strong Buy highlight momentum potential amid positive South Korean market sentiment.
The stock presents value characteristics with a P/E of 9.68 and P/B below 1.0, supported by robust cash flow generation. However, elevated EV/EBITDA at 21.71 and mixed analyst consensus (33% Buy, 67% Hold) suggest cautious optimism. Key risks include interest rate sensitivity given the banking sector exposure and potential macroeconomic headwinds affecting international operations.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
